Pfizer begins COVID vaccine trials for children 5 to 11 years of age .

Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. 

 

 Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier.

This is a 2-year study, where a subset of the children enrolled in the trial will receive the COVID-19 vaccine, and a second group will receive a placebo or salt water as part of the Phase 2/3 trials. The Pfizer vaccine injected in children is the same as the one injected in adults, but the dosage will be less.

Pfizer's trial is focused on detecting the antibody response to the COVID-19 vaccine, and verifying if a lower dosage produces enough immunity for this group. Children 5 to 11-years-old will be injected with 10 micro grams in each dose, as opposed to 30 micro grams those 12 and older received.

Dr. Yvone Maldonado is the principal investigator at Stanford University School of Medicine for the Pfizer trial. Dr. Maldonado said they've received an influx of interested families.